In a recent development, a pharma penny stock that was previously adjusted below Rs 25 due to a 1:1 bonus and 1:5 split has seen a significant rise. The stock, which was trading at Rs 206 before the adjustment, has hit a 20% upper circuit on its ex-date. This surge in price is a positive sign for investors who have been closely monitoring the stock’s performance.